Stockreport

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com
PDF Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cir [Read more]